302 related articles for article (PubMed ID: 36207846)
21. Clinical impact of minimal residual disease and genetic subtypes on the prognosis of childhood acute lymphoblastic leukemia.
Yu CH; Jou ST; Su YH; Coustan-Smith E; Wu G; Cheng CN; Lu MY; Lin KH; Wu KH; Chen SH; Huang FL; Chang HH; Wang JL; Yen HJ; Li MJ; Chou SW; Ho WL; Liu YL; Chang CC; Lin ZS; Lin CY; Chen HY; Ni YL; Lin DT; Lin SW; Yang JJ; Ni YH; Pui CH; Yu SL; Yang YL
Cancer; 2023 Mar; 129(5):790-802. PubMed ID: 36537587
[TBL] [Abstract][Full Text] [Related]
22. [Multi-center trial based on SCMC-ALL-2005 for children's acute lymphoblastic leukemia].
SHAQ Multicenter Study Group of Children's Acute Lymphoblastic Leukemia Research
Zhonghua Er Ke Za Zhi; 2013 Jul; 51(7):495-501. PubMed ID: 24267129
[TBL] [Abstract][Full Text] [Related]
23. Extended vincristine and dexamethasone pulse therapy may not be necessary for children with TCF3-PBX1 positive acute lymphoblastic leukaemia.
Wan Y; Zhang H; Zhang L; Cai J; Yu J; Hu S; Fang Y; Gao J; Jiang H; Yang M; Liang C; Jin R; Tian X; Ju X; Hu Q; Jiang H; Li H; Wang N; Sun L; Leung AWK; Wu X; Wang J; Li CK; Yang J; Tang J; Shen S; Zhai X; Pui CH; Zhu X
Br J Haematol; 2022 Nov; 199(4):587-596. PubMed ID: 36114009
[TBL] [Abstract][Full Text] [Related]
24. Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis.
Sasaki K; Jabbour EJ; Ravandi F; Short NJ; Thomas DA; Garcia-Manero G; Daver NG; Kadia TM; Konopleva MY; Jain N; Issa GC; Jeanis V; Moore HG; Garris RS; Pemmaraju N; Cortes JE; O'Brien SM; Kantarjian HM
Cancer; 2016 Dec; 122(23):3650-3656. PubMed ID: 27479888
[TBL] [Abstract][Full Text] [Related]
25. [Prognostic significance and risk factors of minimal residual disease ≥1% on 19th day of induction chemotherapy in children with acute lymphoblastic leukemia].
Yu J; Yi T; Lin G; Wen J; Chen L; Chen J; Wu X
Nan Fang Yi Ke Da Xue Xue Bao; 2020 Feb; 40(2):255-261. PubMed ID: 32376526
[TBL] [Abstract][Full Text] [Related]
26. Early and delayed consolidation chemotherapy significantly improves the outcome of children with intermediate risk acute lymphoblastic leukemia. Final results of the prospective randomized PETHEMA ALL-89 TRIAL.
Ortega JJ; Ribera JM; Oriol A; Bastida P; González ME; Calvo C; Egurbide I; Hernández Rivas JM; Rivas C; Alcalá A; Besalduch J; Maciá J; Gardella S; Carnero M; Lite JM; Casanova F; Martinez M; Fontanillas M; Feliu E; San Miguel JF;
Haematologica; 2001 Jun; 86(6):586-95. PubMed ID: 11418367
[TBL] [Abstract][Full Text] [Related]
27. Treating childhood acute lymphoblastic leukemia without cranial irradiation.
Pui CH; Campana D; Pei D; Bowman WP; Sandlund JT; Kaste SC; Ribeiro RC; Rubnitz JE; Raimondi SC; Onciu M; Coustan-Smith E; Kun LE; Jeha S; Cheng C; Howard SC; Simmons V; Bayles A; Metzger ML; Boyett JM; Leung W; Handgretinger R; Downing JR; Evans WE; Relling MV
N Engl J Med; 2009 Jun; 360(26):2730-41. PubMed ID: 19553647
[TBL] [Abstract][Full Text] [Related]
28. [Clinical features and prognosis of ETV6-RUNX1-positive childhood B-precursor acute lymphocyte leukemia].
Zheng YZ; Pan LL; Li J; Chen ZS; Hua XL; Le SH; Zheng H; Chen C; Hu JD
Zhonghua Xue Ye Xue Za Zhi; 2021 Jan; 42(1):45-51. PubMed ID: 33677868
[No Abstract] [Full Text] [Related]
29. [Interim results of a multicenter cohort study for Chinese Children Leukemia Group-acute lymphoblastic leukemia 2018 regimen].
Chinese Children Leukemia Group
Zhonghua Er Ke Za Zhi; 2023 Oct; 61(10):874-880. PubMed ID: 37803853
[No Abstract] [Full Text] [Related]
30. Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0622.
Slayton WB; Schultz KR; Kairalla JA; Devidas M; Mi X; Pulsipher MA; Chang BH; Mullighan C; Iacobucci I; Silverman LB; Borowitz MJ; Carroll AJ; Heerema NA; Gastier-Foster JM; Wood BL; Mizrahy SL; Merchant T; Brown VI; Sieger L; Siegel MJ; Raetz EA; Winick NJ; Loh ML; Carroll WL; Hunger SP
J Clin Oncol; 2018 Aug; 36(22):2306-2314. PubMed ID: 29812996
[TBL] [Abstract][Full Text] [Related]
31. [Prognostic factors of pediatric patients with Ph-positive acute lymphoblastic leukemia].
Xue YJ; Wu J; Zuo YX; Jia YP; Lu AD; Zhang LP
Zhonghua Xue Ye Xue Za Zhi; 2018 Mar; 39(3):219-224. PubMed ID: 29562467
[No Abstract] [Full Text] [Related]
32. Differing Outcomes of Patients with High Hyperdiploidy and ETV6-RUNX1 Rearrangement in Korean Pediatric Precursor B Cell Acute Lymphoblastic Leukemia.
Lee JW; Kim S; Jang PS; Chung NG; Cho B
Cancer Res Treat; 2021 Apr; 53(2):567-575. PubMed ID: 33070555
[TBL] [Abstract][Full Text] [Related]
33. Reduced intensity of early intensification does not increase the risk of relapse in children with standard risk acute lymphoblastic leukemia - a multi-centric clinical study of GD-2008-ALL protocol.
Li XY; Li JQ; Luo XQ; Wu XD; Sun X; Xu HG; Li CG; Liu RY; Sun XF; Chen HQ; Lin YD; Li CK; Fang JP
BMC Cancer; 2021 Jan; 21(1):59. PubMed ID: 33435902
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and prognostic factors of imatinib plus CALLG2008 protocol in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.
Lou Y; Ma Y; Li C; Suo S; Tong H; Qian W; Mai W; Meng H; Yu W; Mao L; Wei J; Xu W; Jin J
Front Med; 2017 Jun; 11(2):229-238. PubMed ID: 28349299
[TBL] [Abstract][Full Text] [Related]
35. Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome-positive acute lymphoblastic leukemia.
Jeha S; Coustan-Smith E; Pei D; Sandlund JT; Rubnitz JE; Howard SC; Inaba H; Bhojwani D; Metzger ML; Cheng C; Choi JK; Jacobsen J; Shurtleff SA; Raimondi S; Ribeiro RC; Pui CH; Campana D
Cancer; 2014 May; 120(10):1514-9. PubMed ID: 24501014
[TBL] [Abstract][Full Text] [Related]
36. Allogeneic Stem Cell Transplantation versus Tyrosine Kinase Inhibitors Combined with Chemotherapy in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
Wang J; Jiang Q; Xu LP; Zhang XH; Chen H; Qin YZ; Ruan GR; Jiang H; Jia JS; Zhao T; Liu KY; Jiang B; Huang XJ
Biol Blood Marrow Transplant; 2018 Apr; 24(4):741-750. PubMed ID: 29247779
[TBL] [Abstract][Full Text] [Related]
37. [The Best Time of Minimal Residual Disease Monitoring for Predicting Survival and Prognosis in Children with T-Cell Acute Lymphoblastic Leukemia].
Bao H; Li TY; Wu YT; Xiao ZT; Zhang L; Luo LY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Oct; 29(5):1471-1477. PubMed ID: 34627426
[TBL] [Abstract][Full Text] [Related]
38. A sequential approach with imatinib, chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia: final results of the GIMEMA LAL 0904 study.
Chiaretti S; Vitale A; Vignetti M; Piciocchi A; Fazi P; Elia L; Falini B; Ronco F; Ferrara F; De Fabritiis P; Luppi M; La Nasa G; Tedeschi A; Califano C; Fanin R; Dore F; Mandelli F; Meloni G; Foà R
Haematologica; 2016 Dec; 101(12):1544-1552. PubMed ID: 27515250
[TBL] [Abstract][Full Text] [Related]
39. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Ravandi F; O'Brien SM; Cortes JE; Thomas DM; Garris R; Faderl S; Burger JA; Rytting ME; Ferrajoli A; Wierda WG; Verstovsek S; Champlin R; Kebriaei P; McCue DA; Huang X; Jabbour E; Garcia-Manero G; Estrov Z; Kantarjian HM
Cancer; 2015 Dec; 121(23):4158-64. PubMed ID: 26308885
[TBL] [Abstract][Full Text] [Related]
40. [Comparison of the efficacy of two chemotherapy protocols for children with TEL-AML1[STBZ] fusion gene positive acute lymphoblastic leukemia].
Wang KL; Mei YY; Cui L; Gao C; Liu FF; Zhao XX; Li WJ; Jiang J; Zhang RD; Xie J; Shi HW; Wang B; Zhang YH; Ma XL; Wu MY; Zhou X; Li ZG
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Apr; 22(2):285-90. PubMed ID: 24762993
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]